Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study
December 16, 2019 15:15 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-601 CR Active Ingredient, Tianeptine, is Approved and Marketed as an Immediate Release Three-Times-a-Day Antidepressant in Europe, Asia, Russia and Latin America First Efficacy Trial Planned...
Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL
December 11, 2019 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European...
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
December 10, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Interim Analysis Results Expected Second Half 2020 Topline Results Expected First Half 2021 Based on the Currently-Planned Sample Size NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Tonix...
Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event
December 04, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at the 12th Annual LD Micro...
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
December 03, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, today announced that it has regained...
Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD
November 26, 2019 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
Minutes are Consistent with Guidance Received at FDA Meeting More Than 50 Percent of Enrollment Completed for Phase 3 RECOVERY Trial of Tonmya for PTSD Results from RECOVERY Interim Analysis...
Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference
November 25, 2019 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer...
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
November 21, 2019 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that, having...
Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder
November 20, 2019 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has received the...
Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering
November 20, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), clinical-stage biopharmaceutical company, announced today the closing of its...